The compounds of Formula I act as MGAT2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

##STR00001##

The compounds of Formula I act as MGAT2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

##STR00001##

Compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of disease or conditions in which HNE is implicated

Compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of disease or conditions in which HNE is implicated

The present invention relates to a compound represented by formula (I) of a resorcinol derivative as an HSP90 inhibitor or pharmaceutically accepted salts thereof. The compound in the present invention has the activity of inhibiting heat shock protein HSP90. Therefore, the compound in the present invention is used to treat proliferative diseases such as cancer and neurodegenerative diseases. The present invention further provides the compounds and preparation methods for pharmaceutical compositions comprising the compounds, a method for treating diseases, and pharmaceutical compositions comprising the compounds.

##STR00001##

The present invention relates to a compound represented by formula (I) of a resorcinol derivative as an HSP90 inhibitor or pharmaceutically accepted salts thereof. The compound in the present invention has the activity of inhibiting heat shock protein HSP90. Therefore, the compound in the present invention is used to treat proliferative diseases such as cancer and neurodegenerative diseases. The present invention further provides the compounds and preparation methods for pharmaceutical compositions comprising the compounds, a method for treating diseases, and pharmaceutical compositions comprising the compounds.

##STR00001##

The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. Additional, the present invention provides novel intermediates useful for said process and processes for preparing the same.

The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. Additional, the present invention provides novel intermediates useful for said process and processes for preparing the same.

Metal-chelating compositions having the structure (1a) wherein: R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are independently selected from the following groups: (i) hydrogen atom, (ii) hydrocarbon groups (R) containing 1-12 carbon atoms; (iii) halogen atoms; (iv) —P(R.sup.5) (═O)OH groups; (v) —C(═O)OH groups; (vi) —S(═O).sub.2OH groups; and (vii) —OH groups, wherein R.sup.5 is selected from hydrocarbon groups (R) and —OH; R.sup.1 and R.sup.2 may optionally interconnect to form Ring A fused to the ring on which R.sup.1 and R.sup.2 are present; R.sup.3 and R.sup.4 may optionally interconnect to form Ring B fused to the ring on which R.sup.3 and R.sup.4 are present; wherein Ring A and Ring B are optionally and independently substituted with one or more of groups (ii)-(vii). Methods of using the above-described compositions for chelating metal ions having an atomic number of at least 56 (e.g., Ba or Ra) are also described. ##STR00001##

Metal-chelating compositions having the structure (1a) wherein: R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are independently selected from the following groups: (i) hydrogen atom, (ii) hydrocarbon groups (R) containing 1-12 carbon atoms; (iii) halogen atoms; (iv) —P(R.sup.5) (═O)OH groups; (v) —C(═O)OH groups; (vi) —S(═O).sub.2OH groups; and (vii) —OH groups, wherein R.sup.5 is selected from hydrocarbon groups (R) and —OH; R.sup.1 and R.sup.2 may optionally interconnect to form Ring A fused to the ring on which R.sup.1 and R.sup.2 are present; R.sup.3 and R.sup.4 may optionally interconnect to form Ring B fused to the ring on which R.sup.3 and R.sup.4 are present; wherein Ring A and Ring B are optionally and independently substituted with one or more of groups (ii)-(vii). Methods of using the above-described compositions for chelating metal ions having an atomic number of at least 56 (e.g., Ba or Ra) are also described. ##STR00001##